These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24389179)

  • 1. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.
    Berdeja JG
    Front Biosci (Landmark Ed); 2014 Jan; 19(1):163-70. PubMed ID: 24389179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
    Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
    MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
    Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
    Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
    Geller JI; Pressey JG; Smith MA; Kudgus RA; Cajaiba M; Reid JM; Hall D; Barkauskas DA; Voss SD; Cho SY; Berg SL; Dome JS; Fox E; Weigel BJ
    Cancer; 2020 Dec; 126(24):5303-5310. PubMed ID: 32914879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.
    Ailawadhi S; Kelly KR; Vescio RA; Jagannath S; Wolf J; Gharibo M; Sher T; Bojanini L; Kirby M; Chanan-Khan A
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):29-34. PubMed ID: 30340993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
    Wood AC; Maris JM; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Wu J; Kurmasheva RT; Whiteman K; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Nov; 60(11):1860-7. PubMed ID: 23798344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-maytansinoid conjugates for the treatment of myeloma.
    Lutz RJ; Whiteman KR
    MAbs; 2009; 1(6):548-51. PubMed ID: 20068397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F; Haeder T; Wartenberg-Demand A; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):372-380. PubMed ID: 30930134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
    Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
    Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
    Milowsky MI; Galsky MD; Morris MJ; Crona DJ; George DJ; Dreicer R; Tse K; Petruck J; Webb IJ; Bander NH; Nanus DM; Scher HI
    Urol Oncol; 2016 Dec; 34(12):530.e15-530.e21. PubMed ID: 27765518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
    Robak P; Robak T
    BioDrugs; 2016 Apr; 30(2):87-93. PubMed ID: 26927803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
    Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
    Rodon J; Garrison M; Hammond LA; de Bono J; Smith L; Forero L; Hao D; Takimoto C; Lambert JM; Pandite L; Howard M; Xie H; Tolcher AW
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):911-9. PubMed ID: 18301896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
    Schönfeld K; Zuber C; Pinkas J; Häder T; Bernöster K; Uherek C
    J Hematol Oncol; 2017 Jan; 10(1):13. PubMed ID: 28077160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
    Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
    Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.